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Abstract
Background: Studies examining the transmission of multidrug-resistant tuberculosis (MDR-TB) strains have yielded
conflicting results.
Methods: We examined transmission of MDR-TB strains using contact tracing data from a low incidence setting.
Contacts of MDR-TB cases diagnosed in British Columbia, Canada, from 1990-2008 were identified through a
provincial tuberculosis (TB) registry. Tuberculin skin test (TST) results and TB disease incident rates were determined
for contacts. For comparison, TB disease incident rates and TST results were measured in close contacts of isoniazid
mono-resistant (HMR-TB) and drug susceptible TB (DS-TB) cases.
Results: Of 89 identified close contacts of MDR-TB patients, 5 patients (6%) developed TB disease and 42 (47%)
were TST positive. The incidence rate of TB disease (3%, p = 0.31) and TST positivity (49%, p = 0.82) were similar in
contacts of HMR-TB cases. Compared with MDR-TB contacts, DS-TB contacts had lower incidence rate of TB disease
(2%, p = 0.04) and TST positivity (32%, p < 0.01). All MDR-TB contacts with culture positive TB diagnosed in follow-up
were drug-susceptible; three of six HMR-TB contacts with culture positive TB were HMR-TB. Multivariate analysis
demonstrated that contact with MDR-TB (adjusted OR 1.72; 95%CI 1.05-2.81) and HMR-TB (adjusted OR 1.99; 95%CI
1.48-2.67) was associated with TST positivity. In addition, adult age, male gender, BCG positivity, source case sputum
smear positivity, foreign birth and fewer contacts per source case were significantly associated with TST positivity in
the multivariate model.
Conclusion: Contacts of MDR-TB and HMR-TB patients in a low incidence setting show high rates of TST positivity
and TB disease but low rates of drug resistance.
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Background
Multidrug-resistant tuberculosis (MDR-TB) refers to dis-
ease caused by Mycobacterium tuberculosis strains with
in vitro resistance to both isoniazid (INH) and rifampin,
two first line anti-tuberculosis drugs. The World Health
Organization (WHO) estimates that there were 650,000
MDR-TB cases worldwide in 2008, corresponding to
3.6% of all tuberculosis (TB) cases [1]. MDR-TB is
associated with high rates of patient default, treatment
failure and death [2]. Moreover, MDR-TB treatment is
more costly when compared with first line therapy and
requires enhanced clinical and laboratory support [1].
For these reasons, MDR-TB is a threat to achieving suc-
cessful TB control [3].
Transmission of MDR-TB strains has been examined
from several perspectives, including in vitro and animal
studies, mathematical modeling and epidemiological in-
vestigation [4]. Results from epidemiological studies have
been variable [4,5]. In studies utilizing molecular typing,
drug-resistant strains demonstrate both increased and
decreased clustering [6-12], while data from traditional
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contact tracing studies note variable proportions of tu-
berculin skin test (TST) positivity and TB disease in
MDR-TB contacts [13-20].
Contact tracing studies consistently report a significant
proportion of contacts with TB disease that demonstrate
a distinct resistance profile from their identified MDR-
TB source, indicating that not all supposed transmission
events involve MDR-TB strains [12,14-20]. Despite this
discrepancy, there is considerable evidence to support
human-to-human MDR-TB strain transmission. Indeed
over half of global MDR-TB cases are thought to result
from primary transmission [21]. Yet appropriate pre-
ventative treatment of MDR-TB contacts remains un-
clear, as the relative infectivity MDR-TB strains is
unknown and no high quality evidence exists to guide
treatment of latent TB infection (LTBI) in contacts of
drug resistant cases [22].
We examined local MDR-TB contact tracing outcomes
in a low incidence setting. To better understand the
transmissibility of MDR-TB strains, the proportion of
close contacts of MDR-TB source that developed TB
disease or were found to be TST positive in follow-up
was compared to the proportion of close contacts of




The study was conducted in British Columbia (BC), a
Canadian province with a population of 4.4 million and
a TB case rate of 7.1 per 100 000 population per year
[23]. The BC Centre for Disease Control (BCCDC)
maintains a provincial population based TB registry that
is informed of all TB cases through legal notification, as
well as case notification through a centralized provincial
mycobacteriology laboratory and pharmacy. The same
agency dispenses all medications used to treat contacts.
Contact tracing was performed according to Canadian
guidelines and was recorded in the registry using stan-
dardized protocols [24].
Bacterial culture and susceptibility testing
M. tuberculosis was isolated from clinical specimens
using the BacT/Alert mycobacterial culture detection
system (BioMerieux, Durham, NC). Phenotypic suscepti-
bility testing was performed using the BACTEC 460
radiometric method and interpreted as per Clinical and
Laboratory Standards Institute (CLSI) recommendations
[25,26].
Definitions
For the purposes of this study, a source case was defined
as the first household member to present with culture-
positive pulmonary TB and drug susceptibility profile
results. The source case date of diagnosis was defined as
the date that the first culture positive sample was
received by the laboratory. A close contact was defined
as any individual identified as a “household contact” or
“Type 1 contact” of a source case in the provincial TB
registry. In this registry, both “household contact” and
“Type 1 contact” represent a close contact and refer to
household contacts or those sharing airspace with the
source case for >4 hours per week. TSTs were performed
according to Canadian guidelines [24]. A positive TST in
a given contact was defined as any TST ≥5 mm mea-
sured <3 months before to <1 year after source diagno-
sis. Prior positive referred to a positive TST ≥3 months
before source diagnosis. A close contact identified by the
source case without a TST measurement or TB disease
diagnosis was recorded as no result. Contacts with a
positive TST or with signs and symptoms of TB disease
were screened with a chest x-ray and in some cases, spu-
tum examination. Contacts with TB disease was defined
as a contact with M. tuberculosis complex demonstrated
on culture or an individual with radiological, patho-
logical or therapeutic responses consistent with TB dis-
ease as per established guidelines. Contacts with TB
disease were not classified by their TST result.
Data acquisition and analysis
We accessed the BCCDC registry for all cases of MDR-
TB, HMR-TB and DS-TB diagnosed between 1990 and
2008. Close contacts of all MDR-TB cases were identi-
fied from the registry and their demographic profile,
clinical features and TST results were recorded. For
comparison, close contacts of DS-TB and HMR-TB were
also identified with data recorded in a similar fashion.
Only close contacts were recorded to limit bias intro-
duced by enhanced contact tracing of drug-resistant
sources. To further limit bias introduced by misclassifi-
cation of close contacts, any sources with >15 close con-
tacts were excluded from analysis.
The number of contacts with TB disease was recorded,
and when available, contact resistance profiles were
compared with their purported source case. TST posi-
tive or TST negative contacts with two sources listed
within the same household in the same year were
excluded from further TST analysis. BCG status was
extracted for each contact, along with demographic vari-
ables. When BCG status was unavailable (in 36% of
cases), BCG status was estimated from www.bcgatlas.org
using data on country of origin, age and year of entry to
BC [25,26].
Statistical analysis
Descriptive statistics were computed using Stata version
11.1 (StataCorp, College Station, Texas). The Wilcoxon
Rank Sum test, chi-square test and Ficher’s exact test
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were used in univariate analysis to assess statistical dif-
ference between variables (alpha 0.05). A multivariable
logistic regression model was constructed to test the as-
sociation between source resistance profile and TST
positivity. Factors known to predict TST positivity, in-
cluding adult age (≥18 years), source smear status (posi-
tive), male gender, foreign birth, and BCG status were
included in the model. After analysis of contact data, the
number of contacts per source was added to the model,
as the number of contacts varied significantly between
HMR contacts and DS-TB contacts. A second model
was constructed which excluded BCG status given
the limited data for this variable. Odds ratios with
95% confidence intervals were reported. Models were




We identified 35 MDR-TB cases from the BCCDC regis-
try between 1990 and 2008 (Table 1). Contact tracing
was not performed for 7 cases: 5 had extra-pulmonary
TB, 1 case entered BC on MDR-TB therapy, and 1 case
left BC before contact tracing was initiated. From the
remaining 28 MDR-TB sources, 89 close contacts were
identified, with a median of 3 total contacts per source
(range 1-7) and median follow-up of 123 months (range
19-239). Of the 89 close contacts, 42 (47%) were TST
positive, 33 (37%) were TST negative and 9 (10%) were
prior positive or no result (Table 2). Latent TB therapy
was completed in 12 MDR-TB contacts, including 11
contacts that initiated preventative therapy tailored to
the source case susceptibility profile. Five close contacts
developed TB disease during follow-up; fully susceptible
M. tuberculosis was isolated from 4 cases and the fifth
case was diagnosed based on clinical criteria. All 5 con-
tacts with TB disease were diagnosed within 3 months of
source diagnosis and had not received preventative
therapy.
Isoniazid-resistant and drug-susceptible populations
Between 1990 and 2008, contact tracing of 96 infectious
HMR-TB source cases yielded 249 close contacts, of
whom 121 (49%) were TST positive (Table 2) and 8 (3%)
developed TB disease during follow-up. Of the six con-
tacts with culture-confirmed TB, 3 developed HMR-TB,
while 3 developed DS-TB (Table 3). DS-TB contact tra-
cing over the same period yielded 7309 close contacts
from 2895 sources (Table 2). There were 2321 contacts
(32%) with a positive TST and 168 (2%) contacts with
TB disease. Despite a common median of 3 close con-
tacts per source case, the distribution of contacts varied
significantly between DS-TB and HMR-TB (p < 0.001).









Source Cases 2895 96 28
Household contacts 7309 249 89
Median contacts/source 3 3 3 <0.001^ 0.839^
Source Characteristic
Source Smear Positive 4709 (64) 139 (56) 57 (64) 0.005 0.939
Contact Characteristics
Demographics
Mean Age (Sd) 32.9 (21.2) 28.9 (20.4) 26.7 (19.1)
Age Over 18 5489 (75) 170 (68) 57 (64) 0.013 0.015
Male Gender 3521 (48) 112 (45) 43 (48) 0.32 0.98
Birth Country
Canadian born 3163 (43) 87 (35) 60 (67) 0.001 0.001
Foreign born 3609 (49) 154 (62) 23 (26)
Unknown 536 (7) 8 (3) 6 (7)
BCG status*
Positive 3340 (46) 132 (53) 44 (49) 0.101 0.752
Negative 2977 (41) 94 (38) 42 (47)
Unknown 991 (14) 23 (9) 3 (3)
^Wilcoxon rank sum test.
* 22% of values were calculated using age, country of origin and information from www.bcgatlas.org.
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Multivariate analysis of TST results
All seven pre-specified variables predicted TST positivity
in the logistic regression model, including adult age (OR
1.76; 95% CI 1.51-2.06), male gender (OR 1.18; 95% CI
1.05-1.32), BCG vaccination (OR 1.42; 95% CI 1.23-
1.64), foreign birth (OR 5.37; 95% CI 4.55-6.33), source
smear positivity (OR 1.23; 95% 1.09-1.39), source HMR-
TB (OR 2.13; 95% CI 1.57-2.90), and source MDR-TB
(OR 1.75; 95% CI 1.07-2.86) (Table 4). The number of
close contacts attributed to the index case was included
in the model because the distribution varied significantly
between the HMR-TB and DS-TB groups, and because a
lower threshold for classifying contacts as Type 1 may
impact the rate of TST positivity. Each single increase in
the number of close contacts was associated with a de-
crease in TST positivity (OR 0.96; 95% CI 0.94-0.98).
Estimates did not change significantly after BCG status
was excluded from the model. Chi-square goodness of
fit was non-significant for models that included and
excluded BCG status, indicating that the goodness-of-fit
for this model appeared adequate (p = 0.32, p = 0.09
respectively).
Discussion
Guidelines addressing latent TB infection (LTBI) treat-
ment in MDR-TB contacts are vague and somewhat
contradictory [24,27,28]. The WHO, citing the unknown
efficacy of tailored preventative regimens, recommends
observing contacts with careful clinical follow-up over
two years [28]. The American Thoracic Society recom-
mends observation or treatment with one of two regi-
mens for 6-12 months [27]. These recommendations
reflect the lack of high quality evidence required to dir-
ect decisions. Indeed, a recent Cochrane review failed to
identify randomized control trials on MDR-TB contact
tracing, while a 2006 systematic review found only two
comparative studies suitable for analysis [23,29].
Given our results, combined with the discouraging
completion rates of susceptibility-profile tailored regi-
mens [30-32], IPT could be seen as a potential option in
close contacts of MDR-TB patients in low incidence set-
tings. This strategy, however, is not without risk [33].
MDR-TB transmission does occur in low incidence set-
tings [12]. Moreover, in high incidence settings, the ma-
jority of patients with TB disease in MDR-TB contact
populations develop MDR-TB [16,18,19]. Such contacts
will not likely benefit from IPT. More importantly, how-
ever, this strategy could propagate drug-resistant disease
by selectively killing drug sensitive organisms [34-37].









Source cases 2895 96 28
Close contacts 7309 249 89
TST positive 2321 (32) 121 (49) 42 (47) <0.001 0.002
Secondary case 168 (2) 8 (3) 5 (6) 0.347 0.039
Prior positive 448 (6) 12 (5) 8 (9) 0.395 0.265
No result 475 (6) 9 (4) 1 (1) 0.067 0.045





Isoniazid Rifampin Ethambutol Streptomycin
MDR-TB1 0.1 2.0 4.0 S
S S S S
MDR-TB2 0.1 2.0 NR S
S S S S
MDR-TB3 0.1 2.0 4.0 S
S S S S
MDR-TB4 0.4 2.0 2.5 S
S S S S
MDR-TB5 0.4 2.0 2.5 S
S S S S
HMR-TB1 0.1 S S S
0.1 S S S
HMR-TB2 0.1 S S S
0.1 S S S
HMR-TB3 0.1 S S S
S S S S
HMR-TB4 0.1 S S S
S S S S
HMR-TB5 0.1 S S S
0.1 S S S
HMR-TB6 0.1 S S S
S S S S
The first row in each pair represents source case sensitivity profile, while the
second represents the secondary case susceptibility. S = sensitive, NR = no
result. Resistance values reported in microG/microL.
Table 4 Multivariate analysis of factors associated with
TST positivity
Variable Adjusted OR p-value 95% CI
Age over 18 1.77 <0.001 1.53 - 2.06
Male gender 1.19 0.002 1.07 - 1.33
Foreign birth 6.97 <0.001 6.11 - 7.95
HMR-source 1.99 <0.001 1.48 - 2.67
MDR-source 1.72 0.030 1.05 - 2.81
Smear positive source 1.23 0.001 1.09 - 1.38
Increase in source contacts
(per contact)
0.96 <0.001 0.95 - 0.98
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Thus, the risk of IPT appears to outweigh its benefit in
MDR-TB contacts.
Our results demonstrate that MDR-TB contacts have
higher rates of TST positivity compared with DS-TB
contacts. This may reflect the increased transmissibility
of MDR-TB strains. Alternatively, the high rates of TST
positivity in MDR-TB and HMR-TB contacts may reflect
differential distribution of unmeasured determinants for
LTBI, such as source time-to-diagnosis, source cavitary
disease or contact environmental and socioeconomic
determinants. Indeed the development of DS-TB in all
close contacts of MDR-TB with incident TB disease sup-
ports the notion that close contacts of drug-resistant
source cases may be at higher risk for LTBI and TB dis-
ease independent of transmission from an identified
MDR-TB source case.
There are several limitations in our study, the most
significant being the lack of molecular typing data,
which could help determine whether the discrepant drug
susceptibility profiles were from strains with the same
genotype. A second limitation is the small population of
drug-resistant cases and contacts available for analysis.
Previous studies examining traditional contact tracing in
MDR-TB patients have demonstrated disease rates ran-
ging from 0-8% in close contacts, consistent with
our data [10-19]. However, in studies examining drug-
susceptibility profiles, 62-92% of contacts that
subsequently developed active disease had MDR-TB
[13-16,18-20]. These rates are consistent with data
demonstrating that 70% of secondary cases have the
same genotype as their source case [38].
Finally, data on several determinants for TB infection
are absent from analysis, including time-to-diagnosis,
socioeconomic status and medical co-morbidities. Differ-
ential rates of TST positivity may be, in part, related to
the differential distribution of these determinants. None-
theless, our data suggests that risk for M. tuberculosis in-
fection is higher in the contacts of drug resistant cases,
and that thorough contact tracing should be performed
in this population.
Conclusions
In conclusion, we described our experience with the
contact tracing results of drug-resistant TB in a low
prevalence region over nearly two decades. Our findings
demonstrate that close contacts of MDR-TB at higher
risk for LTBI and active TB. We suggest enhanced con-
tact tracing in MDR-TB contacts, but caution against
IPT in this population. Further research is urgently
needed to determine the optimal management of LTBI
in MDR-TB contacts.
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